Intraperitoneal infusion of either anti‐PD‐1 (200 μg per mouse) or V‐9302 (400 μg per mouse) significantly reduced tumor growth, while the difference between the two treatment groups was not significant (Figure 8B). This evidence concerns the gene PDCD1 and neoplasm.